CCCC C4 Therapeutics Inc

USD 6.16 0.13 2.155887
Icon

C4 Therapeutics Inc (CCCC) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 6.16

+0.13 (+2.16)%

USD 0.41B

1.58M

USD 9.33(+51.52%)

USD 5.67 (-7.95%)

Icon

CCCC

C4 Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 6.16
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.41B

USD 5.67 (-7.95%)

USD 6.16

C4 Therapeutics Inc (CCCC) Stock Forecast

Show ratings and price targets of :
USD 9.33
(+51.52%)

Based on the C4 Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for C4 Therapeutics Inc is USD 9.33 over the next 12 months. C4 Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of C4 Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, C4 Therapeutics Inc’s stock price was USD 6.16. C4 Therapeutics Inc’s stock price has changed by -5.08% over the past week, +45.28% over the past month and +65.59% over the last year.

No recent analyst target price found for C4 Therapeutics Inc
No recent average analyst rating found for C4 Therapeutics Inc

Company Overview C4 Therapeutics Inc

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailabl...Read More

490 Arsenal Way, Watertown, MA, United States, 02472

145

December

USD

USA

Adjusted Closing Price for C4 Therapeutics Inc (CCCC)

Loading...

Unadjusted Closing Price for C4 Therapeutics Inc (CCCC)

Loading...

Share Trading Volume for C4 Therapeutics Inc Shares

Loading...

Compare Performance of C4 Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CCCC

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To C4 Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing CCCC

Symbol Name CCCC's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About C4 Therapeutics Inc (CCCC) Stock

Based on ratings from 3 analysts C4 Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and 2 hold ratings.

Unfortunately we do not have enough data on CCCC's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for CCCC is USD 9.33 over the next 12 months. The maximum analyst target price is USD 14 while the minimum anlayst target price is USD 6.

Unfortunately we do not have enough data on CCCC's stock to indicate if its overvalued.

The last closing price of CCCC's stock was USD 6.16.

The most recent market capitalization for CCCC is USD 0.41B.

Based on targets from 3 analysts, the average taret price for CCCC is projected at USD 9.33 over the next 12 months. This means that CCCC's stock price may go up by +51.52% over the next 12 months.

We can't find any ETFs which contains C4 Therapeutics Inc's stock.

As per our most recent records C4 Therapeutics Inc has 145 Employees.

C4 Therapeutics Inc's registered address is 490 Arsenal Way, Watertown, MA, United States, 02472. You can get more information about it from C4 Therapeutics Inc's website at https://www.c4therapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...